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SUMMARY

Kappa opioid receptors (KORs) are involved in a variety of aversive behavioral states, including anxiety.
To date, a circuit-based mechanism for KOR-driven
anxiety has not been described. Here, we show that
activation of KORs inhibits glutamate release from
basolateral amygdala (BLA) inputs to the bed nucleus of the stria terminalis (BNST) and occludes
the anxiolytic phenotype seen with optogenetic
activation of BLA-BNST projections. In addition,
deletion of KORs from amygdala neurons results in
an anxiolytic phenotype. Furthermore, we identify a
frequency-dependent, optically evoked local dynorphin-induced heterosynaptic plasticity of glutamate
inputs in the BNST. We also find that there is cell
type specificity to the KOR modulation of the BLABNST input with greater KOR-mediated inhibition of
BLA dynorphin-expressing neurons. Collectively,
these results provide support for a model in which
local dynorphin release can inhibit an anxiolytic
pathway, providing a discrete therapeutic target for
the treatment of anxiety disorders.
INTRODUCTION
Anxiety disorders are a major health concern, with 7.3% of the
global population suffering from an anxiety disorder at any given
time (Baxter et al., 2013; Lépine, 2002). Despite the high expense
of anxiety disorder treatments (Lépine, 2002), many of the most
common treatments, including tricyclic antidepressants, mono-

amine oxidase inhibitors, benzodiazepines, and selective serotonin reuptake inhibitors, have side effects that limit their utility
(Ravindran and Stein, 2010). In light of these limitations, there
has been a greater effort to discover new modulatory systems
for the treatment of anxiety disorders (Deisseroth, 2014; Holden,
2003; Johansen, 2013; Tye et al., 2011). To develop new
and more efficacious therapeutics, however, a more thorough
understanding of the circuitry underlying anxiety disorders is
required.
Kappa opioid receptors (KORs) have been proposed as a potential target for stress and anxiety disorders, as well as substance abuse disorders (Wee and Koob, 2010). An abundance
of behavioral pharmacological experiments have shown the
anxiolytic effect of KOR antagonists are capable of overcoming
the anxiogenic effects of a chronic or acute stressor, ethanol
withdrawal, corticotropin-releasing factor (CRF), and KOR agonism (Bruchas et al., 2009; Knoll et al., 2007; Valdez and Harshberger, 2012). Findings have implicated recruitment of KOR
signaling by its endogenous ligand dynorphin (Chavkin et al.,
1982) as playing a key role in preclinical and clinical models of
anxiety (Knoll et al., 2011); however, the mechanism that underlies this effect and the circuitry involved has not yet been defined
(Crowley and Kash, 2015). KOR modulation has been identified
in key anxiety-related regions such as the dorsal raphe nucleus
(Bruchas et al., 2010; Land et al., 2009), the ventral tegmental
area (Spanagel et al., 1992), and the prefrontal cortex (Svingos
and Colago, 2002; Tejeda et al., 2013). These regions interact
with the bed nucleus of the stria terminalis (BNST), a key region
involved in anxiety-related behaviors (Kash, 2012); however,
thus far investigation of KORs in the BNST has been lacking.
In addition, the BNST is known to express preprodynorphin
(Poulin et al., 2009), and previous work from our lab has demonstrated KOR modulation of GABAergic transmission in the BNST
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(Li et al., 2012a). Together, these studies support the idea that
KORs in the BNST could be a promising and important target
for neuropsychiatric manipulations.
Based on the abundance of evidence implicating KORs in anxiety disorders, and the known role of the BNST in regulating anxiety-like behavior, we evaluated the role of KOR modulation of
glutamate transmission in the BNST. We also examined the ability of local BNST dynorphin neurons to heterosynaptically modulate glutamatergic transmission. Here, we report that KORs in the
BNST inhibit glutamatergic transmission on the basolateral
amygdala (BLA) but not the prefrontal cortex (PFC) inputs.
We also demonstrate alterations in anxiety-related behaviors
through complementary manipulations of KORs and this circuit.
Furthermore, we identify a technological approach to assessing
peptidergic transmission in slice.
RESULTS
KORs Signal via a Presynaptic, p38-, and
Calcium-Dependent Mechanism to Inhibit Glutamate
Release in the BNST
An extensive body of literature links glutamate signaling in the
BNST to both anxiolytic and anxiogenic behavior (Davis et al.,
2010; Hubert and Muly, 2014; Kim et al., 2013). Therefore, we
first examined whether KOR activation could alter glutamate
function in the BNST. We found that multiple KOR-selective agonists (Dynorphin-A and U69,593) inhibited electrically-evoked
excitatory post-synaptic currents (eEPSCs) in the BNST, both
of which were blocked by pre-application of the selective
KOR antagonist norbinaltorphimine (norBNI) (Figures 1A–1D).
This KOR-mediated inhibition was not reversed by norBNI (Figures 1E and 1F), suggesting that this is a form of long-lasting
plasticity. We next assessed the intracellular signaling mechanism of this KOR modulation, because KORs have been shown
to signal through both p38 (Bruchas et al., 2007) and MAPK/
extracellular signal-regulated kinase and extracellular signalregulated kinase 1/2 (MEK/ERK) (Li et al., 2012a). p38 signaling
in particular is necessary for the dysphoria associated with KOR
activation (Bruchas et al., 2007). The KOR agonist effect was
blocked in the presence of the p38 inhibitor SB203580 but
not the MEK/ERK inhibitor SL-327 (Figure 1G) or the protein kinase A (PKA) inhibitor RP-Camps (Figure 1H). Together, these
results suggest that KOR-mediated inhibition of glutamate
function in the BNST involves p38 but not MEK/ERK or PKA
signaling.
We next determined the impact of KOR agonists on miniature excitatory synaptic transmission to more clearly understand the mechanism of inhibition. KOR activation reduced
miniature EPSC frequency but not amplitude, with no alterations in miniature EPSC kinetics (Figures 1I–1K). This KOR
modulation of mEPSCs was absent when recordings were
conducted in zero calcium conditions similar to those previously published (Figures 1L and 1M). Taken together, this
demonstrates a presynaptic, p38-, and calcium-dependent
form of glutamate inhibition, mechanistically similar to a form
of long-term depression (LTD) that has been seen in the dorsal
striatum following activation of opioid receptors (Atwood et al.,
2014).

KORs Inhibit Pathway-Specific Glutamate Inputs to the
BNST
Glutamatergic innervation to the BNST arises from multiple
cortical and subcortical nuclei (Dong et al., 2001; Kim et al.,
2013). We next probed KOR inhibition of two of these pathways,
the PFC and the BLA. We injected ChR2 (AAV2-CaMKIIa-ChR2eYFP) in either the BLA or PFC and conducted slice electrophysiology experiments in the BNST. Independent activation of these
pathways produced a robust, light-evoked EPSC, consistent with
other studies examining BLA projections (Felix-Ortiz et al., 2013)
(Figures 2A–2C). The light-evoked BLA-BNST EPSC was inhibited by KOR activation, whereas the light-evoked PFC-BNST
EPSC not altered by KOR agonist (Figure 2D), demonstrating
that KOR modulation of glutamate transmission is pathway
specific. Optogenetic activation of the BLA input to the BNST produced action potentials in BNST neurons reliably up to 20–40 Hz
(Figure 2E). Because we have shown that KOR activation can
inhibit GABA release (Li et al., 2012b), we wanted to test whether
activation of KOR signaling would lead to a net reduction of BLAinduced action potentials in the BNST. Consistent with a net inhibitory action of KOR on this pathway, the KOR agonist significantly
reduced the fidelity of these BLA-BNST-induced action potentials. This demonstrates that presynaptic KORs show specificity
in inhibition of glutamate inputs in the BNST.
KORs Are Expressed Presynaptically and Modulate
BLA-BNST Anxiety-Related Behaviors
Next, we investigated the role of KORs in this pathway in vivo and
in vitro using a genetic approach. We injected AAV5-CaMKIIa-CreGFP (Cre) or AAV5-CaMKIIa-ChR2-eYFP (Control) into the amygdala of conditional KOR knockout mice (Chefer et al., 2013) and
assessed changes in anxiety-related behavior (Figures 3A–3C).
Viral deletion of KORs expressed on amygdala neurons resulted
in an increase in elevated plus maze (EPM) open arm time (Figure 3C) with no alteration in total distance traveled (Figure 3D). In
these experiments targeting neurons in the BLA, there was expression of the cre virus in both the CeA and adjacent cortex in subsets
of animals; however, the expression in these regions did not
correlate to any behavioral measures. In order to confirm the presynaptic locus of KOR modulation at BLA-BNST synapses in vitro,
we injected a cocktail of CaMKIIa-ChR2-eYFP and CaMKIIa-CreGFP into the BLA of KOR KO mice. This approach deletes KORs
expressed on amygdalar neurons, while simultaneously allowing
us to optogenetically activate this specific circuit in slice electrophysiology experiments. KOR-mediated inhibition of the BLA input
was absent when KORs were genetically deleted from the BLA
(Figure 3E). Together, this confirms that KORs are expressed
presynaptically on BLA neurons, and demonstrates that deletion
of amygdala KORs results in an anxiolytic phenotype.
To further understand the role of BNST KORs in anxietyrelated behavior, we next probed this system using in vivo optogenetics (Figure 3F). Optogenetic activation of the BLA-BNST
pathway produced a robust anxiolytic effect in the open field,
replicating the effects found by others (Kim et al., 2013).
Following administration of a sub-anxiogenic dose of the KOR
agonist U50,488 (5 mg/kg intraperitoneally [i.p.]), activation of
the BLA-BNST-induced anxiolytic phenotype, as well as locomotor behavior, was reduced as compared to control mice
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Figure 1. KOR Activation Inhibits Glutamate Transmission in the BNST
(A) Representative experiment demonstrating KOR-mediated inhibition of eEPSC amplitude. Inset: eEPSC trace from the same neuron showing pre- (black) and
post- (red) 1 mM U69,593 application. Scale bar represents 200 pA by 20 ms.
(B) KOR activation by U69,593 inhibited eEPSC amplitude (red circles, paired t test, baseline versus min 21–25, t4 = 30.70, p < 0.001) and was blocked by
continuous application of the KOR antagonist norBNI, 100 nM (yellow circles, paired t test, baseline versus min 21–25, t4 = 0.003, p > 0.05); the KOR agonist
U69,593 significantly inhibited eEPSC amplitude as compared to the norBNI block effect (unpaired t test, acsf versus norBNI, min 16–20, t8 = 10.22, p < 0.001).
(C) Representative experiment demonstrating KOR inhibition by 300 nM Dynorphin-A.
(D) KOR activation by 300 nM Dynorphin-A produces a robust inhibition of eEPSCs (red circles, paired t test, baseline versus min 21–25, t4 = 18.65, p < 0.001) that
is blocked by the KOR antagonist norBNI (yellow circles, paired t test, baseline versus min 21–25, t4 = 2.783, p = 0.05) mimicking the results seen with U69,593
(Figure 1B).
(E and F) Both U69,593 (E) and Dynorphin-A (F) activation of KORs are nonreversible forms of inhibition. Post-U69,593 application of the KOR antagonist norBNI
(100 nm) failed to reverse the inhibition by either KOR agonist (U69,593, paired t test, baseline versus min 21–25, t4 = 13.88, p < 0.001; Dynorphin-A, paired t test,
baseline versus min 21–25, t4 = 14.30, p < 0.001).
(G) The p38 inhibitor SB203580 (10 mM) but not the MEK/ERK inhibitor SL-327 (20 mM) blocked KOR-mediated inhibition of eEPSCs (SB203580 effect, baseline
versus min 16–20, t4 = 2.619, p > 0.05; SL-327 effect, baseline versus min 16–20, t4 = 14, p < 0.0001).
(H) The PKA inhibitor RpCamps (5 mM) does not alter eEPSC amplitude (paired t test, baseline versus min 16–20, t4 = 10, p = 0.0004).
(I) Representative mEPSC traces (top and bottom) pre- (left) and post- (right) U69,593 application, conducted in 500 nM TTX and 5 mM picrotoxin. No significant
changes in mEPSC decay kinetics were seen (not shown, paired t test, t6 = 0.8170, p > 0.1).
(J and K) mEPSC frequency (J) (paired t test, t5 = 5.567, p < 0.001) but not amplitude (K) (paired t test, t5 = 0.2141, p > 0.1) was reduced following application of the
KOR agonist U69,593. Raw values for mEPSC frequency (not shown, baseline frequency mean = 3.406, SEM = 3.475; post-U69,593 frequency mean = 2.179,
SEM = 1.118) and amplitude (not shown, baseline amplitude mean = 29.36, SEM = 1.944, post-U69,593 amplitude mean = 25.71, SEM = 1.465).
(L and M) This inhibition is abolished in zero calcium aCSF, where both frequency (L) (paired t test, t5 = 1.959, p > 0.05) and amplitude (M) (paired t test, t5 = 2.017
p > 0.05) of mEPSCs remain unaltered by U69,593.

(Figures 3G–3I). Together, these complementary behavioral approaches demonstrate that, globally, KORs are an important
regulator of the BLA-BNST anxiety circuit, and that BLA KORs
are critically involved in anxiogenic behavior.
Dynorphin Is a Heterosynaptic Messenger in the BNST,
and Dynorphin Neurons Are Preferentially Modulated by
KORs on BLA to BNST Synapses
Finally, we assessed the capacity of dynorphin neurons in the
BNST to release dynorphin following optogenetic stimulation.

We stereotaxically injected ChR2 using a Cre-dependent vector
(AAV5-EF1a-DIO-ChR2-EYFP) in the BNST of PreprodynorphinIRES-Cre mice (Al-Hasani et al., 2015; Krashes et al., 2014).
Dynorphin-positive (DYN+) neurons were located throughout
the dorsal-lateral BNST (Figure 4A). Light activation of these cells
reliably produced action potentials up to 20 Hz and resulted in a
monosynaptic inhibitory postsynaptic current (IPSC; mean =
422.9, SEM = 149.0), but no EPSC (mean = 17.64, SEM =
6.414) (Figure 4B) onto neighboring, putatively non-dynorphin
(DYN ) neurons, indicating BNST DYN+ neurons form robust
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Figure 2. KOR-Mediated Inhibition
eEPSCs Is Pathway Specific

of

(A) Left: representative injections of ChR2 to the
BLA and expression in the BNST. Right: representative traces for light-evoked EPSCs from the
BLA (top, blue) and PFC (bottom, green).
(B) Both the PFC and BLA send robust glutamatergic projections to the BNST, which do not
differ in amplitude (unpaired t test, t8 = 1.901,
p > 0.05).
(C) The BLA sends a monosynaptic EPSC
and significantly time-delayed polysynaptic IPSC
(paired t test, t7 = 5.232, p < 0.01), comparable to
BLA projections to other outputs.
(D) Similarly, the PFC sends a monosynaptic EPSC
and a significantly time-delayed polysynaptic
IPSC (paired t test, t4 = 4.138, p < 0.05).
(E) KOR activation inhibits BLA-BNST lightevoked EPSC amplitude (paired t test, baseline
versus min 16–20, t4 = 14.86, p < 0.0001). However, KOR application did not alter PFC-BNST
light-evoked EPSC transmission (paired t test,
baseline versus min 16–20, t4 = 0.6899, p > 0.1)
(F) U69,593 reduces the fidelity of light-evoked
BLA-BNST action potentials. When fitted with
standard linear regression, the slope was significantly non-zero predrug application (F1,28 = 12.86,
p < 0.01) but not post (F1,28 = 2.472, p > 0.05). The
lines also showed significant different intercept
points (F1,57 = 5.51, p < 0.05). Inset, representative
traces of action potential fidelity at 20 Hz 5 ms light
stimulation pre- (dark blue) and post- (light blue)
U69,593 application. Black boxes indicate light
pulses.

local synapses that are exclusively GABAergic. We next probed
whether optogenetic activation of these DYN+ neurons was
capable of altering electrically evoked glutamate release within
the BNST. A 5 Hz activation of DYN+ neurons for 150 s produced
a transient norBNI-sensitive (KOR-mediated) inhibition of
eEPSCs (Figure 4C); however, the EPSC amplitude returned to
baseline within minutes. A 20 Hz stimulation for 150 s produced
a robust and lasting inhibition of eEPSCs (Figure 4D); this inhibition was blocked by pre-application of the selective KOR antagonist norBNI. This effect was indistinguishable from that seen
with KOR agonist application (Figures 1A–1D). This effect was
not seen when an identical approach was performed assessing
a GABAergic dynorphin projection to the BNST from the paraventricular nucleus of the hypothalamus (PVN) (Figure 4E).
A 20 Hz activation of PVN-BNST dynorphin neurons did produce

an inhibition of eEPSCs, but this inhibition
was not KOR-dependent, suggesting that
another modulatory system may be playing a role in this distal inhibition by dynorphin neurons (Bodnar, 2013). Taken
together, these experiments demonstrate
that activation of local BNST dynorphin
neurons can inhibit electrically evoked
glutamatergic transmission in the BNST.
Additionally, these experiments suggest
a possible timing-dependent component in the persistence of
KOR plasticity, similar to what has been demonstrated with
norepinephrine-induced LTD in the BNST (McElligott and
Winder, 2008).
Next, we assessed the relationship between BLA inputs to
the BNST and BNST dynorphin neurons. To assess the BLA
inputs onto DYN+ and DYN
neurons separately, ChR2
(AAV2-CaMKIIa-ChR2-eYFP) was injected into the BLA and a
cre-dependent fluorophore (AAV5-EF1a-DIO-mCherry) was injected into the BNST of Preprodynorphin-IRES-Cre mice (Figure 4F). DYN+ neurons had smaller membrane resistance than
their DYN counterparts, and a trend toward significant differences in cell capacitance (Figures S1A and S1B), consistent
with known classifications of BNST neuron types (Hammack
et al., 2007). DYN neurons had more action potentials per
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Figure 3. Deletion of KORs from Amygdala Neurons Increases Anxiolytic Behavior in the EPM and Blocks KOR Agonist-Induced Reduction of
BLA to BNST Inputs, while Systemic Activation of KORs Occludes BLA-BNST-Driven Anxiolytic Behavior in the Open Field
(A) Top: outline of experimental procedure. Floxed KOR mice were injected with either Control or Cre (behavior) or a cocktail of ChR2 and Cre (electrophysiology)
bilaterally to the BLA. Following ample time for virus to express, experiments were conducted. Bottom: representative injection of Cre-GFP into the BLA of floxed
KOR mice.
(B) Representative heatmaps for Control (left) or Cre (right) mice. Enclosed arms are horizontal and open arms are vertical. Scale bar represents intensity of
behavior.
(C) Cre mice showed significantly greater open arm time compared to Control mice (unpaired t test, Cre versus ChR2, t14 = 2.215, p < 0.05).
(D) No differences in total distance traveled were seen (unpaired t test, Cre- versus ChR2, t14 = 0.4226, p > 0.05).
(E) Deletion of KORs from BLA neurons prevented the KOR-mediated inhibition of BLA-BNST synapses, confirming that KORs act pre-synaptically to inhibit
evoked glutamate release. Mice were injected with ChR2 (AAV2-CaMKIIa-ChR2-eYFP) and Cre (AAV2-CaMKII-Cre-GFP) into the BLA, and light-evoked EPSCs
were recorded in the BNST. U69,593 no longer inhibited light-evoked EPSCs (paired t test, baseline versus min. 16–20, t4 = 1.474, p > 0.1). Top, representative
traces from before (black) and after (grey) U69,593 application.
(F) Top: outline of experimental procedure. C57 mice were injected with either ChR2 or eYFP unilaterally to the BLA, and optical fibers were implanted above the
BNST. Following ample time for virus to express, experiments were conducted. Bottom: representative injection of ChR2 into the BLA, and fiber placement in the
BNST. Scale bar represents 100 mM.
(G) A 2-way ANOVA revealed a significant effect of drug (F1,31 = 22.28, p < 0.001) as well as an interaction between drug and ChR2 (F1,31 = 5.210, p < 0.05) on
number of entries into the center of the open field. Tukey’s multiple comparisons showed a significant decrease of entries into the center in ChR2-U50 mice as
compared to ChR2-Saline mice (p < 0.05).
(H) A 2-way ANOVA revealed a trend toward a ChR2 effect (F1,38 = 3.606, p = 0.06) and interaction between ChR2 and drug (F1,38 = 3.097, p = 0.08) on amount of
time spent in the center of the open field. Based on the previous findings, our planned comparisons revealed a significant increase amount of time spent in the
center of the open field of ChR2-Saline mice as compared to eYFP-Saline mice (t17 = 3.034, p < 0.01) and ChR2-U50 mice as compared to ChR2-Saline mice
(t18 = 2.178, p < 0.05), indicating that although ChR2 activation of BLA-BNST neurons produced an anxiolytic effect, this was blocked by the KOR agonist
U50,488. In addition, changes in locomotor behavior were seen in ChR2-U50 and eYFP-U50 mice (data not shown). A 2-way ANOVA revealed a significant effect
of U50,488 treatment on overall activity (F1,30 = 53.91, p < 0.0001). Tukey’s post hoc tests showed that eYFP-U50 mice showed significantly decreased overall
locomotor activity as compared to eYFP-saline mice (p < 0.05). Similarly, as expected, ChR2-U50 mice showed significant decreased overall locomotor as
compared to ChR2-saline controls (p < 0.05).
(I) Representative heatmaps for all groups. Scale bar indicates intensity of behavior.
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Figure 4. Optogenetic Activation of BNST Dynorphin Neurons Inhibits eEPSCs in NonChR2-Expressing Neurons, and KORs Preferentially
Inhibit Glutamate Release onto DYN+ Neurons
(A) Localization of DYN+ neurons in the BNST. DYN+ cells were found throughout the dorsal BNST in a Dyn-L10-EGFP reporter mouse.
(B) Left: local dynorphin cells showed reliable light-evoked action potentials at 20 Hz. These cells synapsed locally, producing a light-evoked IPSC of approximately 423 pA, but no light-evoked EPSC.
(C) 5 Hz stimulation of DYN+ neurons produced a significant transient change in eEPSC amplitude (paired t test, baseline versus min. 5–8, t4 = 6.033, p < 0.05),
which returned to baseline (paired t test, baseline versus min 11–15, t4 = 2.474, p > 0.05).
(D) 20 Hz stimulation of local DYN+ neurons produces a significant and lasting inhibition of eEPSC (paired t test, baseline versus min 11–15, t4 = 10.42, p < 0.001).
This effect is partially blocked by norBNI (unpaired t test acsf versus norBNI block, min 16–20, t8 = 10.59, p < 0.0001).
(E) 20 Hz optogenetic stimulation of PVN to BNST DYN+ neurons produces a significant inhibition of eEPSC (paired t test, baseline versus min 11–15, t4 = 8.566,
p < 0.001) but this was not significantly different from the inhibition seen when in the presence of the KOR antagonist norBNI (unpaired t test, acsf+picrotoxin
versus norBNI block, t8 = 1.191, p > 0.1).
(F) Mice were injected with a cre-inducible mCherry (AAV5-EF1a-DIO-mCherry) to the BNST, and ChR2 (AAV2-CaMKIIa-ChR2-EYFP) to the BLA. Optogenetic
activation of BLA-BNST DYN+ and DYN neurons was then assessed.
(G) Application of the KOR agonist U69,593 significantly reduced the BLA-BNST eEPSC amplitude onto both DYN+ (paired t test, baseline versus min 21–25,
t4 = 12.14, p < 0.001) and DYN neurons (paired t test, baseline versus min 21–25, t4 = 9.039, p < 0.001). However, the effect of KOR-mediated inhibition was
significantly larger on DYN+ neurons compared to DYN neurons (unpaired t test, DYN+ min 21–25 versus DYN 21–25, t8 = 7.071, p < 0.001), indicating KOR
activation in the BNST may preferentially inhibit BLA-DYN+ neurons.
See also Figures S1 and S2.
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current injection when held at RMP, indicative of greater intrinsic
excitability (Figures S1C–S1K). Both DYN+ and DYN neurons
received a glutamate projection from the BLA, as well as a polysynaptic GABAergic projection, but no basal differences were
seen with BLA innervation of these cells as indicated by similar
paired pulse ratio and amplitude of evoked responses (Figures
S2A–S2D). We next examined KOR modulation of BLA inputs
to these two discrete cell types. We found that KOR activation
more robustly inhibited BLA-induced eEPSCs in DYN+ neurons
compared to DYN neurons (Figure 2G). Taken together, these
data suggest that there is both pathway- and cell-type dependent modulation of glutamate function in the BNST by KOR, allowing for important gating of glutamate transmission at DYN+
and DYN neurons.
DISCUSSION
The BNST orchestrates both rewarding and aversive behaviors
(Jennings et al., 2013; Kim et al., 2013). KORs have historically
been thought to modulate aversive (or negatively regulate
rewarding) systems (Chefer et al., 2005) or anxiety-related behaviors, although recent literature has shown that that the neuroanatomical location of KORs may be important in behavioral
effects seen with their activation. Castro and Berridge (2014)
demonstrated that activation of KORs in the nucleus accumbens
can mediate both conditioned place preference and conditioned
place aversion. This work was recently expanded upon when
Al-Hasani et al. (2015) demonstrated that activation of DYN+
neurons themselves in distinct subpopulations of the nucleus accumbens are responsible for rewarding or aversive behavioral
phenotypes and found that photo-activation of the aversive subpopulation of accumbens dynorphin neurons did not results in
anxiogenic behavior. The diversity in effects seen with KOR activation, coupled with the multitude of behavioral outcomes seen
with the BNST activation in this study, places KORs in the BNST
at the interesting and likely position of being able to modulate
anxiety-related behaviors. Furthermore, these results suggest
that KORs are poised to regulate negative affective behavioral
states (aversion) and anxiety via discrete brain subnuclei.
We demonstrate that KOR activation in the BNST inhibits glutamatergic inputs by a presynaptic, p38-, and calcium- dependent mechanism. Previous work has shown p38-dependent
effects of KOR modulation in other brain regions, such as the
dorsal raphe nucleus (Bruchas et al., 2011; Land et al., 2008;
Lemos et al., 2012), and others have postulated that this intracellular signaling pathway may be critical for the dysphoric effects
of KOR agonists (Bruchas et al., 2007). In addition, previous
work by our lab demonstrated that KORs inhibit BNST
GABAergic transmission via MEK/ERK signaling (Li et al.,
2012a). We therefore show that KORs within the BNST are
capable of altering neurotransmitter transmission via pharmacologically distinct mechanisms at different synapses. Differential
use of signaling pathways by KORs has been demonstrated in
the nucleus accumbens (Hjelmstad and Fields, 2003), and these
pharmacologically distinct signaling mechanisms may play a key
role in the development of functionally biased compounds.
Development or identification of biased ligands, capable of targeting individual signaling pathways, may be useful in devel-

oping therapeutic treatments without the unpleasant side effects
seen with KOR activation (White et al., 2014).
Beyond a pharmacologically distinct mechanism of KOR inhibition, we also demonstrate a pathway-specific inhibition of glutamatergic inputs to the BNST. KORs inhibit BLA but not PFC
inputs to the BNST; this mechanism may provide for gating of information flow both to and from the BNST. Future work should
address other inputs to the BNST, including the multitude of inputs recently identified in the human brain (Avery et al., 2014). We
also demonstrate a mechanism by which KORs are activated:
GABAergic/dynorphin co-expressing neurons in the BNST
release dynorphin to presynaptically inhibit glutamate inputs to
the BNST. This signaling mechanism through which dynorphin
regulates transmission may be a common motif throughout the
brain; it was originally postulated to be the mechanism of inhibition in the hippocampus (Drake et al., 1994), and, more recently,
was shown to be the mechanism of inhibition in the PVN (Iremonger and Bains, 2009). We not only show similar findings in
the BNST, but also expand upon this literature by demonstrating
an optogenetic mechanism for activation of such release. This allows for peptidergic and optogenetic coupling, greatly expanding upon the ability to assess peptide release both in vitro and
in vivo.
In addition, we used complementary approaches to identify
behavioral changes in anxiety-related behaviors following manipulations of the KOR system. When KORs were genetically
deleted from BLA neurons using a viral cre approach coupled
with a floxed KOR mouse, we saw a decrease in anxiety-related
behavior in the EPM. Though other projections such as those to
the CeA and hippocampus are likely also important pathways in
this phenotype, the BLA-BNST pathway has been previously
demonstrated to be involved in anxiety-like behavior, as seen
by changes in EPM exploration (Kim et al., 2013). Therefore,
KORs are likely to be a key regulator of this pathway and phenotype. In a complementary series of experiments, we demonstrated in vivo activation of BLA-BNST neurons produced a
robust anxiolytic phenotype (replicating the work by Kim et al.,
2013). Importantly, systemic activation of KORs occludes the
anxiolytic effect seen with BLA-BNST activation; although optogenetic activation of the BLA-BNST pathway can produce a
robust anxiolytic phenotype, this pathway is gated by the dynorphin/KOR system.
Importantly, we found this KOR inhibition exhibited both
cell-type and pathway-dependent differences in function.
Though BLA inputs to the BNST show similar properties
onto both DYN+ and DYN neurons, there is a greater
KOR-mediated inhibition of BLA-DYN+ synapses versus
BLA-DYN synapses. These results suggest a model in which
activation of the BNST by the BLA excites DYN+ neurons, and
this activation leads to a local retrograde release of dynorphin.
This dynorphin release then gates inputs to the BNST, potentially providing a homeostatic balance within the system during
times of heightened activity, suggesting a mechanism by
which KOR antagonists exhibit anxiolytic actions. In addition,
this further illuminates the micro-circuitry of the BNST and
how it may coordinate such a broad range of behavioral
states, such as those involved in stress and addiction. Furthermore, this raises a strategy for development of anxiolytic
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compounds—blocking endogenous inhibitors of defined circuits that reduce anxiety.
Additional work is necessary to elucidate the downstream
effects of BNST dynorphin neurons. Specifically, an understanding is needed of their projection and activation patterns;
this is especially important in light of several recent findings
detailing various sub-domains in the BNST that are linked
with specific behaviors. This work provides an important
framework to begin that research; although the circuitry of
DYN+ and DYN neurons may be equal, their activation and
inhibition may not be. Taken together, this work demonstrates
a pathway specific, p38-, and calcium- dependent form of
KOR inhibition of glutamate. It also demonstrates a mechanism by which local dynorphin release may mediate this
presynaptic effect. Finally, this work shows that KORs may
preferentially inhibit glutamatergic inputs onto DYN+ neurons,
versus DYN neurons, allowing for specific gating of information flow. This circuit-based approach has numerous advantages over existing approaches because it allows higher
precision in defining the substrate and mechanism of action.
Given the lack of efficacious and well-tolerated anxiolytic medications currently available, this work introduces a site-specific
manipulation of the mammalian anxiety system.
EXPERIMENTAL PROCEDURES
Subjects
All animal procedures were performed in accordance with the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill
and the Animal Care and Use Committee of Washington University, conforming to NIH guidelines. Experiments were performed on adult male C57BL/6J
mice and DBA/2J mice, both from Jackson Laboratory. In addition, Preprodynorphin-IRES-Cre and R26-loxSTOPlox-L10-GFP (Al-Hasani et al., 2015;
Krashes et al., 2014), and Floxed KOR conditional knockout mice (Chefer
et al., 2013) were generated as described previously, and bred in house at
UNC. All mice were group housed in colony rooms with a 12:12 hr light-dark
cycle (lights on at 7 a.m.) with ad libitum access to rodent chow and water.
Slice Electrophysiology
Coronal sections containing the BNST (300 mM) were obtained from behaviorally naive mice rapidly decapitated under isoflurane. All experiments were conducted in the dorsolateral portion of the BNST. Lidocaine N-ethyl bromide
(1 mg/ml) was included in the intracellular recording solution to prevent postsynaptic sodium spikes for all voltage-clamp experiments. For basal KOR
pharmacological effects and characterization, picrotoxin (25 mM) was added
to aCSF to isolate EPSCs. Tetrodotoxin (500 nM) and picrotoxin (25 mM)
were added to the aCSF to isolate miniature EPSCs. Cells were held at
70 mV to isolate AMPAR-mediated current (see the Supplemental Experimental Procedures).
For in vitro optogenetic experiments, all brains were evaluated for lightevoked action potentials in the injection region (BLA, PFC, PVN, or BNST)
using a potassium-gluconate-based internal recording solution. Brains were
discarded and not used for further experimentation if action potentials were
not obtained or injection sites were missed. A blue LED (470 nm, CoolLed)
was used to optically stimulate release from channelrhodopsin (ChR2)containing fibers (5 ms pulse for voltage-clamp experiments, 1 ms for current
clamp experiments).
Stereotaxic Surgery
Male mice were injected with viral constructs into regions of interest. A craniotomy was performed, and mice were bilaterally injected using a blunt needle
(86200 and 65458-01, Hamilton), with 400–500 nl of the vector into the BLA
(stereotaxic coordinates from bregma:
1.30 anterior-posterior, ±3.15

medial-lateral, 4.95 mm dorsal-ventral), 350 nl of the vector into the BNST
(stereotaxic coordinates from bregma: +0.27 anterior-posterior, ±0.90
medial-lateral, 4.25 dorsal-ventral), or 400–500 nl of the vector into the
PFC (stereotaxic coordinates from bregma: +1.8 anterior-posterior, ±0.3–0.5
medial-lateral, 2.5 dorsal-ventral). For floxed KOR slice electrophysiology
experiments, ChR2/CRE cocktail was prepared (250 nl ChR2, 250 nl CRE)
and injected into the BLA.
Mice were allowed to recover for at least 6 weeks before behavioral experiments or electrophysiology (see the Supplemental Experimental Procedures).
Behavior
Anxiety-related behavioral assays were conducted as described previously
(Pleil et al., 2015). Briefly, in the first series of experiments, floxed KOR
knockout mice with either ChR2-eYFP or Cre-GFP injected in the BLA were
placed in the EPM for 5 minutes. For these experiments, a virus encoding
ChR2 was injected into control mice, but no in vivo illumination was used. In
the second series of experiments, mice with either ChR2-eYFP or eYFP injected in the BLA with optical fibers in the BNST were systemically administered either saline or a KOR agonist. Thirty minutes later, they were tested in
the open field.
Elevated Plus Maze
The EPM (Med Associates) was made of white-and-black plastic and consisted of two open arms (75 3 7 cm) and two closed arms (75 3 7 3 25 cm)
adjoined by a central area (7 3 7 3 25 cm). The arms were arranged in a
plus configuration with arms of the same type (open or closed) opposite of
each other. The maze was elevated 75 cm with light levels maintained at 15
lux throughout the experiment. Mice were placed in the center of the EPM
and allowed to explore freely. The EPM was cleaned with 70% ethanol between each trial. Movements were video recorded and analyzed using Ethovision 9.0 (Noldus Information Technologies). The primary measures of reduced
anxiety-like behavior were time spent in the open arm and number of entries
into the open arm.
Open Field Test
Mice were injected with the KOR agonist U50,488 (5 mg/kg in saline, i.p.) or
vehicle control (saline) and returned to their home cage for 30 min. The open
field test was performed in a square enclosure (55 3 55 cm) with light levels
maintained at 25 lux. Mice were placed in the center of the open field and
allowed to roam freely for 21 min. Photostimulation alternated between off
and on states in 3 min time segments, beginning with 3 min of no stimulation.
For the photostimulated time segments, animals received 10 Hz (10 ms
width) photostimulation (10 mW light power). The open field was cleaned
with 70% ethanol between each trial. Movements were video recorded and
analyzed using Ethovision 8.5 (Noldus Information Technologies, Leesburg,
VA). The center was defined as a square comprised of 50% the total area of
the open field test. Time in the center was the primary measure of anxietylike behaviors.
Histological Verification
Nissl staining was performed in cohorts of mice used for in vivo optogenetics
to confirm injections and fiber placements (see the Supplemental Experimental Procedures).
Viral Vectors
The viral constructs AAV2-CaMKIIa-ChR2-eYFP, AAV2-CaMKIIa-eYFP,
AAV5-EF1a-DIO-ChR2-eYFP,
AAV5-EF1a-DIO-eYFP,
AAV5-EF1a-DIOChR2-mCherry, AAV5-CaMKIIa-ChR2-eYFP, AAV5-CaMKIIa-Cre-GFP, and
AAV2-CaMKIIa-Cre-eYFP, described elsewhere (Kim et al., 2013), were
obtained from the UNC Viral Vector Core.
Data Analysis and Statistics
Data are expressed as means ± SEM for all figures. For all experiments, 2-way
ANOVAs, paired t tests, unpaired t tests, and linear regression were used
where appropriate, as described in figure captions. Statistical analyses were
conducted using Prism 6.0 (GraphPad), and figures were made in Illustrator
CC 2015 (Adobe).
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